Compare AMETEK, Inc. (AME) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMETEK, Inc. vs Smith & Nephew plc — how do they compare? AMETEK, Inc. trades at $257.95 (market cap $58.76B), while Smith & Nephew plc trades at $29.68 (market cap $12.54B). The key difference: AMETEK, Inc. is far larger — about 4.7× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.65%). Which is the better fit depends on your goals.
| AME | SNN | |
|---|---|---|
Market Cap | $58.76B | $12.54B |
Sector | Industrials | Health |
52-Week High | $256.30 | $38.70 |
52-Week Low | $179.28 | $28.73 |
Enterprise Value | $60.30B | $15.57B |
Dividend Yield | 0.53% | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AME trades at $252.88, down 0.31% on the day, with a bullish technical signal from moving averages and strong support near $252. The company reported Q2 2026 EPS of $2.09, beating estimates, and raised full-year guidance, reflecting robust demand. Revenue grew to $7.4B in 2025, with a net margin of 20.04%, while valuation ratios like P/E of 37.47 suggest a premium. Recent news highlights momentum and inclusion in high-growth themes like 3D printing.
Outlook remains positive given earnings beats and analyst consensus, but risks include elevated valuation and macroeconomic sensitivity. The stock offers growth potential with a $281.86 price target, though investors should monitor execution against guidance and industry competition.
Smith & Nephew (SNN) trades at $30.08, down 0.1% with bearish technical signals. The company reported mixed Q2 2026 results with revenue growth below expectations, leading to a reduced full-year outlook. Fundamentals show strong profitability with 10.1% net margin and improving cash flow trends, though recent earnings misses have tempered sentiment.
Outlook remains cautious with analyst consensus at Hold (65% of coverage). Near-term risks include U.S. orthopedics weakness and competitive pressures, offset by robotics innovation and value-based care expansion. The stock offers stable fundamentals but faces execution challenges in key markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
